Hemorrhage

• 

  Subject Areas on Research

  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. 
  • A Hybrid Approach to Radiation-Induced Axillary Artery Hemorrhage. 
  • A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A Summary of The 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. 
  • A hemorrhage of off-label use. 
  • A joint latent class analysis for adjusting survival bias with application to a trauma transfusion study. 
  • A joint latent class model for classifying severely hemorrhaging trauma patients. 
  • A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. 
  • A midurethral sling to reduce incontinence after vaginal prolapse repair. 
  • A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger? 
  • A mouse bleeding model to study oral anticoagulants. 
  • A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. 
  • A pattern-oriented approach to splenic imaging in infants and children. 
  • A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. 
  • A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. 
  • A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. 
  • A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. 
  • A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. 
  • A risk score to predict bleeding in patients with acute coronary syndromes. 
  • A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • A tale of two centrifugal left ventricular assist devices. 
  • ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Accidental heparinization in the newborn: a case report and brief review of the literature. 
  • Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study. 
  • Acquired hypofibrinogenemia in obstetric hemorrhage. 
  • Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. 
  • Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. 
  • Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. 
  • Active arterial contrast extravasation on helical CT of the abdomen, pelvis, and chest. 
  • Acute dysphonia secondary to vocal fold hemorrhage after vardenafil use. 
  • Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine. 
  • Addressing the Conundrum of Bleeding and Cancer Detection With Antithrombotic Therapies for Chronic Atherosclerotic Cardiovascular Disease. 
  • Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. 
  • Adjuncts to Blood Component Therapies for the Treatment of Bleeding in the Intensive Care Unit. 
  • Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. 
  • Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health. 
  • Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. 
  • Adnexal masses: MR imaging observations at 1.5 T, with US and CT correlation. 
  • Adrenal hemorrhage in patients with primary antiphospholipid syndrome: imaging findings. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. 
  • Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. 
  • Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. 
  • Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. 
  • Algorithm-based management of bleeding in patients with extracorporeal membrane oxygenation. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • An antiplatelet response gene expression signature is associated with bleeding. 
  • An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS). 
  • An infant with subvalvar and valvar aortic stenosis, subvalvar and valvar pulmonary stenosis, severe biventricular hypertrophy and pulmonary hemorrhage. 
  • An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. 
  • An overview of the results of the EPIC trial. 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. 
  • Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Angiography and the pediatric trauma patient: a 10-year review. 
  • Angiosarcoma of the pericardium presenting as hemorrhagic pleuropericarditis, cardiac tamponade, and thromboembolic phenomena. 
  • Animal models of bleeding and tissue repair. 
  • Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. 
  • Anti-inflammatory adjuvant in resuscitation fluids improves survival in hemorrhage. 
  • Anti-inflammatory resuscitation improves survival in hemorrhage with trauma. 
  • Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulants. 
  • Anticoagulation Resumption After Stroke from Atrial Fibrillation. 
  • Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. 
  • Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. 
  • Anticoagulation in COVID-19: It Is Time for High-Quality Evidence. 
  • Anticoagulation in atrial fibrillation. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Anticoagulation techniques in apheresis: from heparin to citrate and beyond. 
  • Anticoagulation, novel agents, and procedures: can we pardon the interruption? 
  • Anticoagulation-Related Major Bleeding in Patients With Atrial Fibrillation: Looking Behind the Curtain. 
  • Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care. 
  • Antidote-mediated control of an anticoagulant aptamer in vivo. 
  • Antifibrinolytic therapy: new data and new concepts. 
  • Antiphospholipid syndrome with catastrophic bleeding and recurrent ischemic strokes as initial presentation of systemic lupus erythematosus. 
  • Antiplatelet Medications Are Associated With Bleeding and Decompensation Events Among Patients With Cirrhosis. 
  • Antiplatelet agents in cardiovascular disease. 
  • Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. 
  • Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. 
  • Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). 
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 
  • Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 
  • Antithrombotic therapy: new areas to understand efficacy and bleeding. 
  • Aortoesophageal fistula after thoracic aortic stent-graft placement: a rare but catastrophic complication of a novel emerging technique. 
  • Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. 
  • Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. 
  • Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 
  • Application of fibrin glue to damaged bladder mucosa in a case of BK viral hemorrhagic cystitis. 
  • Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. 
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. 
  • Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. 
  • Aspirin and reproductive outcomes. 
  • Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. 
  • Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to End-Stage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization-An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program. 
  • Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. 
  • Association Of Bleeding Avoidance Strategies with age-related bleeding and In-hospital mortality in patients undergoing percutaneous coronary Interventions. 
  • Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. 
  • Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. 
  • Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. 
  • Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. 
  • Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. 
  • Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Association of bleeding and in-hospital mortality in black and white patients with st-segment-elevation myocardial infarction receiving reperfusion. 
  • Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. 
  • Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. 
  • Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. 
  • Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. 
  • Atorvastatin-induced hemorrhagic cystitis: a case report. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. 
  • Avoiding complications with radical cystectomy. 
  • B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. 
  • B6 and Bleeding: A Case Report of a Novel Vitamin Toxicity. 
  • Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation. 
  • Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. 
  • Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. 
  • Biomarkers of cavernous angioma with symptomatic hemorrhage. 
  • Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry. 
  • Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study. 
  • Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. 
  • Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? 
  • Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. 
  • Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. 
  • Bleeding and clotting while supported with ECMO: time to move forward. 
  • Bleeding and risk for future cardiovascular events in patients with atrial fibrillation on oral anticoagulation: major bleeding is a major problem. 
  • Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. 
  • Bleeding and thrombotic complications of pediatric liver transplant. 
  • Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. 
  • Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Bleeding disorders in premenopausal women: (another) public health crisis for hematology? 
  • Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Bleeding in acute coronary syndromes. 
  • Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. 
  • Bleeding outcomes of inpatients receiving therapeutic plasma exchange: A propensity-matched analysis of the National Inpatient Sample. 
  • Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients. 
  • Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. 
  • Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. 
  • Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. 
  • Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. 
  • Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. 
  • Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes: a systematic review and meta-analysis. 
  • Blood-induced arterial segmental spasm. 
  • Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group. 
  • CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. 
  • COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. 
  • CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases. 
  • CT appearance of clinically occult abdominal hemorrhage in children. 
  • CT evaluation of lumbosacral plexus disorders. 
  • CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. 
  • Can chorio-retinal biopsy be justified? 
  • Cangrelor use prior to left ventricular assist device surgery: a case series. 
  • Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. 
  • Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. 
  • Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. 
  • Cardiovascular regulation in response to multiple hemorrhages: analysis and parameter estimation. 
  • Case 13--2014: Management of pulmonary hemorrhage after pulmonary endarterectomy with venovenous extracorporeal membrane oxygenation without systemic anticoagulation. 
  • Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations. 
  • Causes of Maternal Mortality in Rwanda, 2017-2019. 
  • Cellular composition of post-haemorrhagic opacities in the human vitreous. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Changing Patterns of Anticoagulation After Total Hip Arthroplasty in the United States: Frequency of Deep Vein Thrombosis, Pulmonary Embolism, and Complications With Rivaroxaban and Warfarin. 
  • Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. 
  • Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. 
  • Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. 
  • Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. 
  • Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. 
  • Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. 
  • Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. 
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. 
  • Classification and initial management of patients with unstable pelvic ring injuries. 
  • Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. 
  • Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. 
  • Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. 
  • Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 
  • Clinical and laboratory manifestations of anti-factor V antibodies. 
  • Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. 
  • Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 
  • Clinical comparison of St. Jude and porcine aortic valve prostheses. 
  • Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. 
  • Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. 
  • Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. 
  • Clinical features and outcomes in patients with cardiogenic shock complicating acute myocardial infarction: early vs recent experience with impella. 
  • Clinical implications of acute pelvicaliceal hematoma formation during percutaneous catheter nephrostomy insertion. 
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. 
  • Clinical use of oral contraceptives administered vaginally: a case report. 
  • Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. 
  • Clopidogrel in infants with systemic-to-pulmonary-artery shunts. 
  • Clopidogrel plus aspirin in atrial fibrillation. 
  • Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. 
  • Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. 
  • Coagulopathy Characterized by Rotational Thromboelastometry in a Porcine Pediatric ECMO Model. 
  • Coagulopathy in COVID-19. 
  • Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection? 
  • Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. 
  • Colonic uptake of Tc-99m MDP in pseudomembranous colitis. 
  • Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. 
  • Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. 
  • Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex. 
  • Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. 
  • Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices. 
  • Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry. 
  • Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. 
  • Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 
  • Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. 
  • Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. 
  • Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. 
  • Comparison of Radial Access, Guided Femoral Access, and Non-Guided Femoral Access Among Women Undergoing Percutaneous Coronary Intervention. 
  • Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. 
  • Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. 
  • Comparison of bleeding and in-hospital mortality in Asian-Americans versus Caucasian-Americans with ST-elevation myocardial infarction receiving reperfusion therapy. 
  • Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. 
  • Comparison of fondaparinux and enoxaparin in acute coronary syndromes. 
  • Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. 
  • Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. 
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 
  • Compensatory response to hemorrhage in conscious dogs on normal and low salt intake. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Complications associated with indwelling catheters. 
  • Complications associated with optical-access laparoscopic trocars. 
  • Complications of cesarean section: role of transperineal US. 
  • Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. 
  • Complications of percutaneous nephrostolithotomy. 
  • Computed tomography of high density renal cysts. 
  • Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial. 
  • Congenital platelet disorder and type I von Willebrand disease presenting as prolonged bleeding after cleft lip and palate repair. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. 
  • Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. 
  • Continuing anticoagulation following venous thromboembolism. 
  • Continuing evolution in the approach to severe liver trauma. 
  • Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients. 
  • Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. 
  • Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation. 
  • Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. 
  • Conversations in cardiology: bridging antiplatelet therapy before surgery. 
  • Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. 
  • Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. 
  • Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. 
  • Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. 
  • Cryoprecipitate transfusion in bleeding patients. 
  • Cullen's and Turner's signs. 
  • Current Approaches in the Management of Hepatic Adenomas. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Current options in oral antiplatelet strategies during percutaneous coronary interventions. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Dabigatran versus warfarin in patients with mechanical heart valves. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. 
  • Death from renal cyst. 
  • Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India. 
  • Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. 
  • Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. 
  • Demonstration and characterization of the hemoconcentrating effect of ascitic fluid that accumulates during hemorrhagic pancreatitis. 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. 
  • Detecting retinal microaneurysms and hemorrhages with robustness to the presence of blood vessels. 
  • Determinants and outcomes of acute transcatheter valve-in-valve therapy or embolization: a study of multiple valve implants in the U.S. PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve). 
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. 
  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. 
  • Development and validation of a predictive model for bleeding after peripheral vascular intervention: A report from the National Cardiovascular Data Registry Peripheral Vascular Interventions Registry. 
  • Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. 
  • Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. 
  • Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. 
  • Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. 
  • Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. 
  • Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials. 
  • Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Direct oral anticoagulants: new drugs and new concepts. 
  • Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Discontinuation and management of direct-acting anticoagulants for emergency procedures. 
  • Disorders of iron metabolism. 
  • Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. 
  • Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? 
  • Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study. 
  • Does moderate hypothermia really carry less bleeding risk than deep hypothermia for circulatory arrest? A propensity-matched comparison in hemiarch replacement. 
  • Does pelvic hematoma on admission computed tomography predict active bleeding at angiography for pelvic fracture? 
  • Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. 
  • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 
  • Dose of prophylactic platelet transfusions and prevention of hemorrhage. 
  • Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. 
  • Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 
  • Drug-induced lung injury. 
  • Drusen of the optic disc. A histopathological study. 
  • Drusen of the optic disc. A retrospective study in cadaver eyes. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. 
  • Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review. 
  • Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. 
  • Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. 
  • Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 
  • Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. 
  • Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 
  • Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. 
  • Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. 
  • Early cryoprecipitate for trauma patients is feasible, but will it improve outcome? 
  • Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. 
  • Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. 
  • Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Editorial for "Perfusion and Permeability Magnetic Resonance Imaging (MRI) Predicts Future Cavernous Angioma Hemorrhage and Growth". 
  • Editorial: Diagnostic considerations in electromechanical dissociation. 
  • Edoxaban versus warfarin in patients with atrial fibrillation. 
  • Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. 
  • Effect of Initial Anticoagulation Targets on Bleeding and Thrombotic Complications for Patients With Acute Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation. 
  • Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial. 
  • Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. 
  • Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. 
  • Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. 
  • Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. 
  • Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial. 
  • Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. 
  • Effect of home testing of international normalized ratio on clinical events. 
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. 
  • Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. 
  • Effectiveness of Glycerol Mono-oleate as a Biosealant. 
  • Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. 
  • Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. 
  • Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. 
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 
  • Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. 
  • Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. 
  • Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. 
  • Effects of pretransplant splenectomy and immunosuppression of humoral immunity in a pig-to-newborn goat cardiac xenograft model. 
  • Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. 
  • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. 
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. 
  • Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. 
  • Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. 
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. 
  • Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency. 
  • Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. 
  • Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 
  • Embolic protection and platelet inhibition during renal artery stenting. 
  • Emergency airway management of tracheo-innominate fistulas in the pediatric population. 
  • Endoscopic sphincterotomy complications and their management: an attempt at consensus. 
  • Endovascular management of inadvertent brachiocephalic arterial catheterization. 
  • Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. 
  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 
  • Estimating Clinical Trial Bleeding Events Using Electronic Health Record Data. 
  • Estimating the ratio of multivariate recurrent event rates with application to a blood transfusion study. 
  • Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. 
  • Ethyl pyruvate prevents inflammatory responses and organ damage during resuscitation in porcine hemorrhage. 
  • Evaluating the Association Between Fibrinogen and Rotational Thromboelastometry and the Progression to Severe Obstetric Hemorrhage. 
  • Evaluation and Management of Blunt Solid Organ Trauma. 
  • Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?). 
  • Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. 
  • Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism. 
  • Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. 
  • Evaluation of effect of scheduled fresh frozen plasma on ECMO circuit life: A randomized pilot trial. 
  • Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. 
  • Evaluation of repeat distal transradial access in the anatomic snuffbox. 
  • Evaluation of several methods for computing stroke volume from central aortic pressure. 
  • Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. 
  • Experimental transvitreal cyanoacrylate retinopexy in a primate model. 
  • Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. 
  • Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials. 
  • Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. 
  • Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis. 
  • Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. 
  • Extracorporeal Membrane Oxygenation for Hemodynamic Support. 
  • Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. 
  • Extracorporeal membrane oxygenation outcomes in children with hemophagocytic lymphohistiocytosis. 
  • Facilitated PCI in patients with ST-elevation myocardial infarction. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Factors influencing plasma transfusion practices in paediatric intensive care units around the world. 
  • Factors influencing survival in pediatric acute leukemia. The SWCCSG experience, 1958-1970. 
  • Factors related to extended hospital stays following deep brain stimulation for Parkinson's disease. 
  • Fatal and nonfatal hemorrhagic complications of living kidney donation. 
  • Fatal pulmonary bile embolism following acute acalculous cholecystitis. 
  • Feasibility of smaller arterial cannulas in venoarterial extracorporeal membrane oxygenation. 
  • Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention. 
  • Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. 
  • Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. 
  • Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Filtering bleb thrombolysis with tissue plasminogen activator. 
  • Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. 
  • Final results of the ReoPro readministration registry. 
  • Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. 
  • First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. 
  • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure-Related Bleeding Events. 
  • Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). 
  • G-protein-coupled receptors as signaling targets for antiplatelet therapy. 
  • GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Genetic factors contribute to bleeding after cardiac surgery. 
  • Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. 
  • Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. 
  • Glutamine therapy improves outcome of in vitro and in vivo experimental colitis models. 
  • Goal-directed coagulation management in the perioperative period of cardiac surgery. 
  • Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. 
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 
  • Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. 
  • Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study: A survey analysis of stakeholder practices, needs, and barriers. 
  • Heavy menstrual bleeding: work-up and management. 
  • Hematologic disorders and nonimmune hydrops fetalis. 
  • Hemorrhage and thrombus formation in early experimental osteonecrosis. 
  • Hemorrhage associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on a regimen of dual antiplatelet therapy: a retrospective analysis. 
  • Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. 
  • Hemorrhage risk with transjugular intrahepatic portosystemic shunt (TIPS) insertion at the main portal vein bifurcation with stent grafts. 
  • Hemorrhagic Herpes Simplex Virus Type 1 Nephritis: An Unusual Cause of Acute Allograft Dysfunction. 
  • Hemorrhagic adrenal adenoma simulating myelolipoma: CT evaluation. 
  • Hemostatic effects of therapeutic plasma exchange: A concise review. 
  • Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 
  • Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage. 
  • Hepatocellular adenomas: Understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. 
  • High-resolution CT of drug-induced lung disease. 
  • High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. 
  • History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. 
  • How I use fibrinogen replacement therapy in acquired bleeding. 
  • How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Humoral rejection of rat hepatic transplants by passive transfer of serum. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal. 
  • Identification of hospital outliers in bleeding complications after percutaneous coronary intervention. 
  • Imaging findings of hemorrhagic cystitis in pediatric oncology patients. 
  • Imaging of complications of thoracic and cardiovascular surgery. 
  • Immediate laparoscopic adrenalectomy versus observation: cost evaluation for incidental adrenal lesions with atypical imaging characteristics. 
  • Immediate versus delayed coronary grafting after streptokinase treatment. Postoperative blood loss and clinical results. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. 
  • Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. 
  • Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. 
  • Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. 
  • Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. 
  • Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. 
  • Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy. 
  • Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. 
  • Impaired haemostasis and regional anaesthesia. 
  • Impella Versus Intra-Aortic Balloon Pump for High-Risk PCI: A Propensity-Adjusted Large-Scale Claims Dataset Analysis. 
  • Implementation and Evaluation of Tactical Combat Casualty Care for Army Aviators. 
  • Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative. 
  • Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. 
  • Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. 
  • In Response. 
  • In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year. 
  • In reply. 
  • In reply. 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. 
  • Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. 
  • Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry. 
  • Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. 
  • Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). 
  • Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes. 
  • Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. 
  • Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. 
  • Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. 
  • Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. 
  • Individual-Specific, Beat-to-beat Trending of Significant Human Blood Loss: The Compensatory Reserve. 
  • Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. 
  • Inflammation does not predispose to bleeding in hemophilia. 
  • Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. 
  • Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. 
  • Initial treatment of patients with extensive trauma. 
  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. 
  • Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). 
  • International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis. 
  • International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. 
  • Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. 
  • Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 
  • Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 
  • Is thrombogenesis related to residual platelet function in ischaemic heart disease? 
  • Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 
  • Laboratory monitoring of high-dose factor VIIa therapy. 
  • Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. 
  • Learning from 2523 trauma deaths in India- opportunities to prevent in-hospital deaths. 
  • Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. 
  • Left Ventricular Assist Devices: A Primer For the General Cardiologist. 
  • Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. 
  • Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. 
  • Letter to the Editor: Managing Dabigatran-Related Bleeding. 
  • Life-long bleeding diathesis: effect of orthotopic liver transplantation. 
  • Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. 
  • Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. 
  • Long-term antithrombotic therapy after venous stent placement. 
  • Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial. 
  • Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial. 
  • Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. 
  • Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. 
  • Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. 
  • Major bleeding: management and risk reduction in acute coronary syndromes. 
  • Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. 
  • Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. 
  • Management of Anticoagulant and Antiplatelet Medications in Adults Undergoing Percutaneous Interventions. 
  • Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). 
  • Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. 
  • Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 
  • Management of adult renal trauma: a practice management guideline from the eastern association for the surgery of trauma. 
  • Management of anticoagulation agents in trauma patients. 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Management of urgent invasive procedures in patients treated with direct oral anticoagulants: An observational registry analysis. 
  • Managing new oral anticoagulants in the perioperative and intensive care unit setting. 
  • Managing oral anticoagulant therapy. 
  • Massive Transfusion Protocol Adherence: Relationship to Trauma Patient Outcomes. 
  • Massive pulmonary hemorrhage after pulmonary thromboendarterectomy. 
  • Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. 
  • Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists. 
  • Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery. 
  • Meta-analysis of drug eluting stents compared with bare metal stents in high bleeding risk patients undergoing percutaneous coronary interventions. 
  • Microdialysis assessment of shock wave lithotripsy-induced renal injury. 
  • Middle-of-the-night percutaneous coronary intervention and its association with percutaneous coronary intervention outcomes performed the following day: an analysis from the National Cardiovascular Data Registry. 
  • Minimizing the risks of anticoagulants and platelet inhibitors. 
  • Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program. 
  • Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. 
  • Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. 
  • Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. 
  • Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. 
  • Multidisciplinary approach to the challenge of hemostasis. 
  • Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. 
  • Mycoplasma pneumoniae-associated diffuse alveolar haemorrhage: an atypical presentation of a prevalent pathogen. 
  • Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. 
  • NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. 
  • Nanosilver composite pNIPAm microgels for the development of antimicrobial platelet-like particles. 
  • Near infrared optical monitoring of intact skeletal muscle during hypoxia and hemorrhagic hypotension in cats. 
  • Near-infrared spectrophotometric monitoring of oxygen distribution to intact brain and skeletal muscle tissues. 
  • Near-miss maternal mortality: cardiac dysfunction as the principal cause of obstetric intensive care unit admissions. 
  • Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. 
  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. 
  • New oral anticoagulant-induced bleeding: clinical presentation and management. 
  • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. 
  • New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. 
  • Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. 
  • Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. 
  • North American Thrombosis Forum, AF Action Initiative Consensus Document. 
  • Novel Murine Models of Cerebral Cavernous Malformations. 
  • Novel insights for systemic inflammation in sepsis and hemorrhage. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. 
  • Novel pharmacologic approaches to reduce bleeding. 
  • NovoSeven for non-hemophilia hemostasis. 
  • Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. 
  • Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Ocular pathology in rainbow trout in Malawi (Zomba disease). 
  • On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. 
  • Optimal pressure of abdominal gas insufflation for bleeding control in a severe swine splenic injury model. 
  • Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Oral factor Xa inhibitors for the long-term management of ACS. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcomes after massive transfusion in nontrauma patients in the era of damage control resuscitation. 
  • Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. 
  • Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. 
  • Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. 
  • Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes. 
  • P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. 
  • P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. 
  • P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. 
  • PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial. 
  • Paediatric rheumatic disease: lessons from SLE: children are not little adults. 
  • Pancreatic polypeptide in acute pancreatitis and small-bowel infarction in dogs. 
  • Parathyroid hormone secretion and target organ response in experimental acute pancreatitis. 
  • Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. 
  • Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm. 
  • Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. 
  • Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. 
  • Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. 
  • Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. 
  • Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. 
  • Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. 
  • Patterns of mortality and causes of death in polytrauma patients--has anything changed? 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. 
  • Percutaneous management of RetroFlex 3 balloon rupture and separation of the Edwards Sapien delivery system. 
  • Percutaneous transhepatic liver biopsy with tract embolization. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient. 
  • Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation. 
  • Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? 
  • Perioperative coagulation management: Evolving strategies. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Perioperative management of the bleeding patient. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. 
  • Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. 
  • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. 
  • Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. 
  • Pharmacologic methods to reduce perioperative bleeding. 
  • Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. 
  • Photocoagulation and local steroid-induced ocular hypertension in the treatment of diabetic retinopathy. 
  • Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. 
  • Placental localisation with 99mTc-labelled red blood cells. 
  • Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. 
  • Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. 
  • Platelet Transfusion Practice and Related Outcomes in Pediatric Extracorporeal Membrane Oxygenation. 
  • Platelet Transfusion Practices in Critically Ill Children. 
  • Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Point of care devices for assessing bleeding and coagulation in the trauma patient. 
  • Point-of-care platelet function analysis ready for prime time? 
  • Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. 
  • Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. 
  • Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock. 
  • Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Post-procedure heparin: boon or burden? 
  • Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial. 
  • Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. 
  • Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. 
  • Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program. 
  • Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. 
  • Prasugrel: Clinical development and therapeutic application. 
  • Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. 
  • Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. 
  • Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®. 
  • Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. 
  • Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. 
  • Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. 
  • Prehospital tourniquet use in Operation Iraqi Freedom: effect on hemorrhage control and outcomes. 
  • Preperitoneal packing for pelvic fracture-associated hemorrhage: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. 
  • Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. 
  • Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. 
  • Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
  • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. 
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. 
  • Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. 
  • Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. 
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. 
  • Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery? 
  • Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. 
  • Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Pulmonary hemorrhage in pediatric patients with systemic lupus erythematosus. 
  • Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. 
  • Pursuing progress in acute coronary syndromes. 
  • Putting risk prediction in atrial fibrillation into perspective. 
  • Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. 
  • Racial differences in long-term outcomes among black and white patients with drug-eluting stents. 
  • Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. 
  • Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. 
  • Radiology of acute diffuse lung disease in the immunocompetent host. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. 
  • Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. 
  • Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. 
  • Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. 
  • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. 
  • Ranibizumab for neovascular age-related macular degeneration. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. 
  • Rear-view mirror observations on bleeding in acute coronary syndromes. 
  • Recent developments in topical thrombins. 
  • Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Recombinant activated factor VIIa treatment for refractory hemorrhage in infants. 
  • Recombinant biologics for treatment of bleeding disorders. 
  • Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. 
  • Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. 
  • Recurrent event frailty models reduced time-varying and other biases in evaluating transfusion protocols for traumatic hemorrhage. 
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 
  • ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Relation between activated clotting time during angioplasty and abrupt closure. 
  • Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. 
  • Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. 
  • Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. 
  • Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. 
  • Renal function, atherothrombosis extent, and outcomes in high-risk patients. 
  • Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. 
  • Reoperative surgery in calves with a total artificial heart. 
  • Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. 
  • Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. 
  • Resistance to antiplatelet drugs: what progress has been made? 
  • Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines. 
  • Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. 
  • Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. 
  • Results of high dose intravenous urokinase for acute myocardial infarction. 
  • Reversal agents for non-vitamin K antagonist oral anticoagulants. 
  • Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate. 
  • Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. 
  • Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? 
  • Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. 
  • Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. 
  • Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. 
  • Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. 
  • Risk of Ischemic Stroke in Patients With Atrial Fibrillation After Extracranial Hemorrhage. 
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. 
  • Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. 
  • Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. 
  • Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. 
  • Risks and Realities of Delayed Splenic Bleeding. 
  • Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. 
  • Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. 
  • Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 
  • Rivaroxaban in Peripheral Artery Disease after Revascularization. 
  • Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. 
  • Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. 
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
  • Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. 
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Rocky mountain spotted fever in childhood. 
  • Role of coagulation factor concentrates for reversing dabigatran-related anticoagulation. 
  • Rotational thromboelastometry-guided blood product management in major spine surgery. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Ruptured popliteal artery aneurysm. 
  • S-nitrosylation therapy to improve oxygen delivery of banked blood. 
  • Safe splenoportography. 
  • Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 
  • Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). 
  • Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis. 
  • Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. 
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. 
  • Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. 
  • Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. 
  • Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease. 
  • Safety of Percutaneous Biopsy for Hepatic Angiosarcoma: Results of a Multicenter Korean Survey. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Safety of recombinant activated factor VII in randomized clinical trials. 
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. 
  • Safety of warfarin dosing in the intensive care unit following the Fontan procedure. 
  • Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. 
  • Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 
  • Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. 
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
  • Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE. 
  • Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. 
  • Severe coagulation abnormalities in Reye syndrome. 
  • Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. 
  • Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. 
  • Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. 
  • Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. 
  • Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS. 
  • Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction. 
  • Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. 
  • Shorter times to packed red blood cell transfusion are associated with decreased risk of death in traumatically injured patients. 
  • Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? 
  • Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). 
  • Sonography of benign cystic teratoma of the ovary: pitfalls in diagnosis. 
  • Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). 
  • Spontaneous necrosis and hemorrhage in an enlarged accessory spleen: CT demonstration. 
  • Spontaneous tonsillar hemorrhage. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. 
  • Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 
  • Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. 
  • Stroke prevention in atrial fibrillation. 
  • Stroke prevention in atrial fibrillation: Closing the gap. 
  • Subconjunctival hemorrhage in bulimia. 
  • Successful prophylactic regimens for transvaginal oocyte retrieval in women with bleeding diatheses. 
  • Sudden death due to undiagnosed T lymphoblastic leukemia/lymphoma in a 5-year-old boy. 
  • Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. 
  • Survival and inflammatory responses in experimental models of hemorrhage. 
  • Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. 
  • Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. 
  • Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry. 
  • Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. 
  • The Association of Frailty With In-Hospital Bleeding Among Older Adults With Acute Myocardial Infarction: Insights From the ACTION Registry. 
  • The Comparison of the Outcomes between Primary PCI, Fibrinolysis, and No Reperfusion in Patients ≥ 75 Years Old with ST-Segment Elevation Myocardial Infarction: Results from the Chinese Acute Myocardial Infarction (CAMI) Registry. 
  • The Developing Balance of Thrombosis and Hemorrhage in Pediatric Surgery: Clinical Implications of Age-Related Changes in Hemostasis. 
  • The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. 
  • The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. 
  • The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry. 
  • The Judicious Use of Recombinant Factor VIIa. 
  • The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices. 
  • The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. 
  • The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. 
  • The balance of thrombosis and hemorrhage in surgery. 
  • The cellular basis of traumatic bleeding. 
  • The central role of thrombin in bleeding disorders. 
  • The challenge of defining bleeding among patients with acute coronary syndromes. 
  • The coagulation cascade in cirrhosis. 
  • The cost effectiveness of a quality improvement program to reduce maternal and fetal mortality in a regional referral hospital in Accra, Ghana. 
  • The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and L-selectin expression. 
  • The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. 
  • The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. 
  • The frequency of transplacental hemorrhage in patients with threatened abortions. 
  • The impact of postrandomization crossover of therapy in acute coronary syndromes care. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • The management of acute coronary syndromes in patients with chronic kidney disease. 
  • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. 
  • The pathology of vitreous hemorrhage. I. Gross and histological appearances. 
  • The pathology of vitreous hemorrhage. II. Ultrastructure. 
  • The pharmacology of novel oral anticoagulants. 
  • The potential of aptamers as anticoagulants. 
  • The rational clinical examination. Is this patient hypovolemic? 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. 
  • The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial. 
  • The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? 
  • The role of prasugrel in the management of acute coronary syndromes: a systematic review. 
  • The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. 
  • The safety of warfarin therapy in the nursing home setting. 
  • The significance of intraocular hemorrhages due to subarachnoid hemorrhage. 
  • The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. 
  • The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature. 
  • Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. 
  • Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. 
  • Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. 
  • Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. 
  • Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. 
  • Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). 
  • Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma. 
  • Thromboembolism and bleeding in bladder cancer. 
  • Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. 
  • Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. 
  • Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. 
  • Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. 
  • Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. 
  • Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. 
  • Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. 
  • Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. 
  • Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. 
  • Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. 
  • Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. 
  • Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 
  • Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. 
  • Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. 
  • Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 
  • Ticagrelor with or without Aspirin in High-Risk Patients after PCI. 
  • Time in Therapeutic Range Significantly Impacts Survival and Adverse Events in Destination Therapy Patients. 
  • Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. 
  • Towards a better standard for defining high bleeding risk patients: can we now translate this into a better practice? 
  • Tracheostomy Practices and Outcomes in Children During Respiratory Extracorporeal Membrane Oxygenation. 
  • Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. 
  • Tranexamic Acid for Acute Hemorrhage: When Is Enough Evidence Enough? 
  • Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? 
  • Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. 
  • Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings. 
  • Transradial PCI in women: problem solved or clinical equipoise? 
  • Trauma-induced coagulopathy. 
  • Traumatic hemorrhage and rapid expansion of a cervical lymphatic malformation. 
  • Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. 
  • Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. 
  • Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. 
  • Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure. 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). 
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. 
  • Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. 
  • Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Tumor necrosis factor-alpha-238G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • Two-year outcomes after transcatheter or surgical aortic-valve replacement. 
  • Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. 
  • Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. 
  • Update on massive transfusion. 
  • Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. 
  • Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. 
  • Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. 
  • Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. 
  • Urologic complications in renal transplantation. 
  • Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. 
  • Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. 
  • Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. 
  • Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of factor concentrates for the management of perioperative bleeding: reply. 
  • Use of fibrin sealant as a hemostatic agent after liver biopsy in swine. 
  • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. 
  • Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. 
  • Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. 
  • Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. 
  • Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. 
  • Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. 
  • Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. 
  • Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. 
  • Vitreous hemorrhage after intracranial hemorrhage. 
  • Vitreous hemorrhage associated with sickle-cell trait and sickle-cell hemoglobin-C disease. 
  • Vitreous membrane formation after experimental vitreous haemorrhage. 
  • Von Willebrand Disease, Hemophilia, and Other Inherited Bleeding Disorders in Pregnancy. 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • Warfarin or aspirin for recurrent ischemic stroke. 
  • Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. 
  • Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. 
  • What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? 
  • What is the evidence for platelet transfusion in perioperative settings? 
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 
  • Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants? 
  • Women and girls with haemophilia: Lessons learned. 
  • Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. 
  • [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Cohen, Seth Morris, Professor of Head and Neck Surgery & Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology
  • Kim, Charles Yoon, Professor of Radiology, Radiology, Interventional Radiology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Olson, Steven Arthur, Goldner Jones Distinguished Professor of Orthopaedic Surgery, Orthopaedic Surgery
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology